TRAINING UPDATE

Lab Location: Department:

SGMC & WAH

Core **Due Date:**

Date Distributed: 8/20/2015 8/31/2015 **Implementation:** 9/1/2015

DESCRIPTION OF PROCEDURE REVISION

Name of procedure:

Cardiac Troponin I by Dimension Vista® System SGAH.C112, WAH.C108 v3

Description of change(s):

Section	Reason
	Specify anticoagulant
4.2	Add hazard warning
6.4, 6.6	Replace LIS with Unity Real Time
11.1	Change upper value from 0.10 to 0.05
11.2	Change critical from ≥ 0.60 to > 0.09

Notes:

- The critical value change was ALREADY made in DI
- Critical value will also be changed for troponin performed on Xpand at GEC **<u>BUT</u>** it will have a different upper value for reference range

This revised SOP will be implemented on September 1, 2015

Document your compliance with this training update by taking the quiz in the MTS system.

Approved draft for training (version 3)

Technical SOP

Title	Cardiac Troponin I by Dimension	Vista® System
Prepared by	Ashkan Chini	Date: 6/25/2012
Owner	Robert SanLuis	Date: 6/25/2012

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
Refer to the electronic signature page for approval and approval		
dates.		

Review		
Print Name	Signature	Date

TABLE OF CONTENTS

1.	Test Information	2
2.	Analytical Principle	3
3.	Specimen Requirements	3
4.	Reagents	
5.	Calibrators/Standards	
6.	Quality Control	
7.	Equipment And Supplies	
8.	Procedure	
9.	Calculations	11
10.	Reporting Results And Repeat Criteria	
11.	Expected Values	
12.	Clinical Significance	
13.	Procedure Notes	
14.	Limitations Of Method	13
15.	Safety	14
16.	Related Documents	14
17.	References	14
18.	Revision History	
19.	Addenda	

1. TEST INFORMATION

Assay	Method/Instrument	Local Code
Troponin I	Dimension Vista® System	TROPI1

Synonyms	/Abbr	eviations
	TANNE	cviations

Troponin, Tropi, CTNI, Included in Batteries/Packages: CIEP4

n	~~		tm		4
.,	en	Яr	11111	en	Н.

Chemistry

2. ANALYTICAL PRINCIPLE

The CTNI method is a homogeneous, sandwich chemiluminescent immunoassay based on LOCI technology. The LOCI reagents include two synthetic bead reagents and a biotinylated anti-cardiac troponin I monoclonal antibody fragment. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with a second anti-cardiac troponin I monoclonal antibody and contains chemiluminescent dye. Sample is incubated with Chemibeads and biotinylated antibody to form bead-cardiac troponin I-biotinylated antibody sandwiches. Sensibeads are added and bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the cardiac troponin I concentration in the sample.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred	Plasma (Lithium Heparin)
-Other Acceptable	Serum
Collection Container	Plasma: Mint green top tube
	Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum	1.0 mL
- Minimum	0.5 mL
Transport Container and	Collection container or Plastic vial at room temperature
Temperature	
Stability & Storage	Room Temperature: 8 hours
Requirements	Refrigerated: 2 days
	Frozen: 8 weeks
	Instrument on board 2 hours
	aliquot stability

Criteria	
Timing Considerations	Serum or plasma should be physically separated from cells as soon as possible with a maximum limit of two hours from the time of collection.
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for "test not performed" message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical	Gross hemolysis. Reject sample and request a recollection.
Characteristics	Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation.

4. REAGENTS

Refer to the Material Safety Data Sheet (MSDS) supplied with the reagents for complete safety hazards. Refer to the section in this procedure covering "SAFETY" for additional information.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Cardiac Troponin I	Siemens, Flex® reagent cartridge, Cat. No. K6421
CTNI Sample Diluent	Siemens Healthcare Diagnostics, Cat. No. KD692

4.2 Reagent Preparation and Storage

NOTES: Each container must be labeled with (1) substance name, (2) lot number, (3) expiration date, (4) any special storage instructions; check for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration. Refer to the Material Safety Data Sheet (MSDS) for a complete description of hazards. If a specific hazard is present, it will be noted in this procedure when the hazard is first encountered in a procedural step.

Irritant. Contains 5-chloro-2-methyl-3(2h)-isothiazolone mixture with 2-methyl-3(2h)- isothiazolone.

May cause an allergic skin reaction.

Wear protective gloves/protective clothing/eye protection/face protection.
Contaminated work clothing should not be allowed out of the workplace. IF ON SKIN: Wash with plenty of soap and water. If skin irritation or rash occurs:

Get medical advice/attention

Reagent	Cardiac Troponin I	
Container	Reagent cartridge	
Storage	Store at 2-8° C	
Stability	 Reagent is stable until expiration date stamped on the reagent cartridges. Sealed wells on the instrument are stable for 30 days. Once wells 1 - 12 have been entered by the instrument, they are stable for 7 days. 	
Preparation	All reagents are liquid and ready to use.	

Reagent	CTNI Sample Diluent	
Container	Reagent plastic bottle	
Storage	Store at 2-8° C	
Stability	 Unopened diluent is stable until expiration date stamped on the reagent bottle. Once opened, diluent is stable for 30 days when recapped and stored at 2-8° C. Do not use this vial on board the instrument. Once the stopper of the vial is punctured, diluent is stable for 30 days on board the instrument. 	
Preparation	CTNI SDIL is ready for use. No preparation is required.	

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
CTNI CAL	Siemens Dimension Vista®, Cat. No. KC678

5.2 Calibrator Preparation and Storage

NOTE: Date and initial all calibrators upon opening. Each container must be labeled with (1) substance name, (2) lot number, (3) date of preparation, (4) expiration date, (5) any special storage instructions; check for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

Calibrator	CTNI CAL	
Preparation	Before use, thaw at room temperature $(22 - 28^{\circ} \text{ C})$, swirl and	
_	invert gently to mix. Do not use glass pipettes when	
	transferring calibrators to sample cups.	
Storage/Stability	• Store at -15°C to -25°C	
	• Unopened calibrator (frozen) is stable until expiration date	

stamped on the box.
• Unopened calibrator (thawed) is stable for 7 days when
stored at 2-8°C
• Opened Calibrator: once the stopper of the vial is
punctured, assigned values are stable for 7 days when stored
on board the Dimension Vista System.
• Opened Calibrator: once cap is removed, assigned values
are stable for 7 days when recapped immediately after use
and stored at 2-8°C. Do not use this vial on board the
instrument.

5.3 Calibration Parameter

Criteria	Special Notations	
Reference Material	CTNI CAL	
Assay Range	0.02 – 40.00 ng/mL	
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in ng/mL	
Frequency	 Every new reagent cartridge lot. Every 30 days for any one lot When major maintenance is performed on the analyzer. When control data indicates a significant shift in assay. 	
Calibration Scheme	6 levels, n = 3	

5.4 Calibration Procedure

Auto Calibration:

- 1. Place the required calibrator vials in a carrier. Make sure the barcode labels are entirely visible through the slots.
- 2. Place the carrier in the loading area.
- 3. Position the carrier with the labels facing away from the user.
- 4. Press the **Load** button.
- 5. Automatic calibration requires that calibrators be on the instrument. As the time for processing approaches, the instrument reviews onboard inventory for the appropriate calibrators.

Manual Calibration:

- 1. Verify that calibrators and reagents are in inventory on the instrument.
- 2. Press **System > Method Summary > Calibration**.
- 3. Select a method from the sidebar menu. Press the **Order Calibration** button on the screen.
- 4. Verify that the information on the screen is correct. Verify that the calibrator lot is correct using the drop-down menu.
 - a. When calibrating using Vials press **OK**.

- b. When calibrating using Cups, check the Use Cups box. This displays the rack and cup position fields. For additional cups use the positions in ascending order. Be sure to use the number of calibration levels and cups as specified in the method IFU. Scan the rack barcode and place calibrator cups in an adapter in position 1 on a rack. Press **OK** and load the rack on the instrument.
- 5. The status field in the calibration screen changes sequentially to Awaiting Scheduling, Preparing Calibrators and Processing.

5.5 Tolerance Limits

IF	THEN
If result fall within assay-specific specification,	proceed with analysis
and QC values are within acceptable limits,	
If result falls outside assay-specific specification,	troubleshoot the assay and/or
or QC values are out of Acceptable limits,	instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
Liquichek TM Cardiac Markers Plus Control	Bio-Rad Laboratories
Levels 1, 2 and 3	Cat # 181, 182 and 183

6.2 Control Preparation and Storage

NOTE: Date and initial all controls upon opening. Each container should be labeled with (1) substance name, (2) lot number, (3) date of preparation, (4) expiration date, (5) initials of tech, and (6) any special storage instructions; check for visible signs of degradation. A barcode label is produced and placed on the vial.

Control	Liquichek Cardiac Markers Plus Controls, Level 1, 2 and 3	
Preparation	Allow the frozen control to thaw at room temperature (18-25°C)	
	until completely thawed. Swirl the contents gently to ensure	
	homogeneity. (Do not use a mechanical mixer)	
	Use immediately. After each use, promptly replace the stopper	
	and return to 2-8°C storage.	
Storage/Stability	Unthawed controls are stable until the expiration date at -20 to	
	-70° C.	
	Once the control is thawed and opened, Troponin I will be stable	
	for 10 days when stored tightly capped at 2-8°C.	

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Dimension Vista® QC Schedule in the Laboratory policy Quality Control Program and in the Dimension Vista® Quick Reference Guide.

6.4 Tolerance Limits

Step	Action	
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.	
2	 Run Rejection Criteria Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem. 	
3	Orrective Action: All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be reanalyzed according to the Laboratory QC Program. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program.	
	Corrective action documentation must follow the Laboratory Quality Control Program.	
4	Review of QC	
	QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee.	
	If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.	

6.5 Review Patient Data

Technologist must review each result with error messages. Refer to the Dimension Vista® system manual "Error messages" section for troubleshooting. Check for unusual patterns, trends, or distributions in patient results (such as an unusually high

percentage of abnormal results). Resolve any problems noted before issuing patient reports.

6.6 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.7 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this
 test. This procedure must be incorporated into the departmental competency
 assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Dimension Vista® System

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -15 to -25°C.
- Centrifuge

7.3 Supplies

Aliquot Plates

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

CTNI Flex® reagent cartridge Cat. No. K6421 is required to perform this test.

Cardiac Troponin I is performed on the Dimension Vista[®] System after the method is calibrated (see Reference Material in Calibration section) and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

8.1	Sample Processing
1.	A sample rack holding tubes or cups is placed on the rack input lane.
2.	The sample shuttle moves the rack to the barcode reader which identifies the rack and samples to the system.
3.	The rack moves into the sample server and to the rack positioner.
4.	At the same time, aliquot plates move from the aliquot loader into position.
5.	The aliquot probe aspirates the sample from the tubes or cups and dispenses it into the wells of the aliquot plates.
6.	After each aspirate-dispense action, the probe is thoroughly rinsed inside and out to prevent sample carryover.
7.	When sample aspiration is completed, the sample server moves the rack back to the sample shuttle, where it is placed on the output lane and can be removed by the
	operator.

8.2	Specimen Testing
1.	For QC placement and frequency, refer to the Dimension Vista® QC Schedule in the Laboratory QC Program.
2.	Follow the instructions, outlined in the Dimension Vista® Operator's Manual
3.	The instrument reporting system contains error messages to warn the user of specific malfunctions. Results followed by such error messages should be held for follow-up. Refer to the Dimension Vista® system manual "Error messages" section for troubleshooting.
4.	Follow protocol in Section 10.5 "Repeat criteria and resulting" for samples with results above or below the Analytical Measurement Range (AMR). Investigate any failed delta result and repeat, if necessary.

8.2	Specimen Testing
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

Test Conditions			
Sample Volume:	20 μL		
Chemibead Reagent Volume:	20 μL		
Biotinylated Antibody Volume:	20 μL		
Sensibead Reagent Volume:	13 μL		
Assay Buffer Volume:	100 μL		
Reaction Time:	10 minutes		
Test Temperature:	37° C		
Wavelength:	680 and 612 nm		
Type of measurement:	Chemiluminescence		

9. CALCULATIONS

The instrument automatically calculates the concentration of Cardiac Troponin I in ng/mL.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results up to two decimal points.

10.3 Units of Measure

ng/mL

10.4 Clinically Reportable Range (CRR)

0.02 - 200.00 ng/mL

10.5 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall within the AMR or CRR may be reported without repeat. Values that fall outside these ranges must be repeated.

IF the result is	THEN		
	Assure there is sufficient sample devoid of bubbles, cellular		
< 0.02 ng/mL	debris, and/or fibrin clots. Report as:		
	< 0.02 ng/mL		
	On Board Automated Dilution:		
$\geq 40.00 \text{ ng/mL}$	Results ≥ 40.00 ng/mL will automatically have repeat testing		
≥ 40.00 lig/lilL	performed into the instrument using dilution factor of 5.		
	No multiplication is necessary.		
	If the recommended dilution does not give results within the		
> 200.00 ng/mI	clinically reportable range, report as: "> 200.00 ng/mL-REP"		
> 200.00 ng/mL	Bring to the attention of your supervisor prior to releasing		
	result.		

Message	Code	
Verified by repeat analysis	Append –REP to the result.	

11. EXPECTED VALUES

11.1 Reference Ranges

 $0.00 - \frac{0.05 \text{ ng/mL}}{}$

11.2 Critical Values

> 0.09 ng/mL

Treatment of **Subsequent critical values** for Troponin-I:

Only the first critical value for each hospital encounter must be called. Subsequent critical values for troponin must be documented by appending the code **TROPC** to the result. This code translates to "Laboratory value indicates a critical value previously reported."

11.3 Priority 3 Limit(s)

None established

12. CLINICAL SIGNIFICANCE

Troponin is the contractile regulatory protein complex of striated muscle. It is found periodically along the thin filament of the myofibrils, in conjunction with the protein tropomyosin. The troponin complex consists of three distinct polypeptide components: troponin-C (the calcium binding element), troponin-I (the actinomyosin ATPase inhibitory element), and troponin-T (the tropomyosin binding element). The complex serves to regulate the calcium dependent interaction of myosin and actin and thus plays an integral role in

muscle contraction. Troponin-I exists in three distinct molecular forms which correspond to specific isotypes found in fast-twitch skeletal muscle, slow-twitch skeletal muscle, and heart, respectively.

Several reports in the literature have indicated that cardiac troponin-I is released into blood within hours of the onset of symptoms of myocardial infarction and that it remains elevated for several days post-infarction. The cumulative data from these reports indicate that troponin-I levels become abnormal 4–8 hours following onset of chest pain, peak at 12–16 hours, and remain elevated for 5–9 days following an infarction.

Measurement of cardiac troponin-I levels provide sensitive and specific determination of myocardial injury over a wide diagnostic window. Elevations in cardiac troponin-I levels have been observed across a spectrum of acute coronary syndromes including Q-wave MI, non-Q-wave MI and unstable angina. A significantly higher incidence of mortality has been observed in patients with non-Q-wave MI and unstable angina who have detectable levels of cardiac troponin-I. This suggests that cardiac troponin-I provides a means for risk stratification of these individuals.

13. PROCEDURE NOTES

FDA Status: FDA Approved/clearedValidated Test Modifications: None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up. Refer to your Dimension Vista Operator's Guide.

The expected maximum observed standard deviations for repeatability using n = 5 replicates at the following Cardiac Troponin I concentrations are:

CTNI Concentration	Acceptable S.D. Maximum
0.5 ng/mL	0.063 ng/mL
8.0 ng/mL	0.939 ng/mL

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

0.02 - 40.00 ng/mL

14.2 Precision

	Mean	Standard Deviation (%CV)		
Material	ng/mL	Repeatability	Within-Lab	
Serum Pool	0.123	0.005 (4.2)	0.007 (5.8)	
Serum Pool	0.55	0.012 (2.3)	0.016 (2.9)	
Serum Pool	31.4	0.95 (3.0)	1.18 (3.8)	

Interfering Substances 14.3

HIL Interference:

The CTNI method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias, defined as the difference between the control sample (does not contain interferent) and the test sample (contains interferent), is shown in the table below. Bias exceeding 10% is considered "interference".

Substance tested	Substance Concentration	CTNI ng/mL	Bias %
Hemoglobin (hemolysate)	500 mg/dL	0.945	<10
Bilirubin (unconjugated)	40 mg/dL	0.907	<10
Bilirubin (conjugated)	40 mg/dL	0.879	<10
Linamia Intustinida	500 mg/dL	0.941	ر10
Lipemia Intralipid®	3000 mg/dL	0.970	<10

14.4 Clinical Sensitivity/Specificity/Predictive Values

Not available

15. **SAFETY**

The employee has direct responsibility to avoid injury and illness at work. Nearly all harmful exposures to infectious substances and chemicals, and other injuries, can be avoided with effective training and consistent safe work practices.

Become familiar with the Environmental Health and Safety (EHS) Manual to learn the requirements on working safely and protecting the environment from harm. Although lab work typically focuses on the hazards of working with specimens and chemicals, we must also control other important hazards.

- Slips, trips, and falls cause many serious injuries. Please ensure that spills are cleaned quickly (to avoid slippery floors) and that you can see and avoid obstacles in your path.
- Ergonomic injuries result from performing tasks with too much repetition, force, or awkward position. Ergonomic injuries include strains and back injuries. Learn about ergonomic hazards and how to prevent this type of injury.
- Scratches, lacerations, and needlesticks can result in serious health consequences. Attempt to find ways to eliminate your risk when working with sharp materials.

Report all accidents and injuries immediately to your supervisor or the business unit Environmental Health and Safety Manager or Specialist.

16. RELATED DOCUMENTS

- 1. Dimension Vista® Clinical Chemistry System Operator's Manual
- Dimension Vista[®] Calibration/Verification Procedure
 Dimension Vista[®] Cal Accept Guidelines
- 4. Dimension Vista[®] Calibration summary
- 5. Dimension Vista® Sample Processing, Startup and Maintenance procedure

- 6. Laboratory Quality Control Program
- 7. QC Schedule for Siemens Dimension Vista®
- 8. Laboratory Safety Manual
- 9. Material Safety Data Sheets (MSDS)
- 10. Dimension Vista[®] Limits Chart (AG.F200)
- 11. Quest Diagnostics Records Management Procedure
- 12. Dimension Vista® System Error Messages Chart
- 13. Centrifuge Use, Maintenance and Function Checks (Lab policy)
- 14. Hemolysis, Icteria and Lipemia Interference (Lab policy)
- 15. Repeat Testing Requirement (Lab policy)
- 16. Critical Values (Lab policy)
- 17. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
- 18. Current package insert CTNI Flex® Reagent Cartridge K6421

17. REFERENCES

- 1. Package Insert, CTNI Flex® Reagent Cartridge K6421, Siemens Healthcare Diagnostics Inc., 3/27/2015.
- 2. Package Insert, CTNI CAL, Siemens Healthcare Diagnostics Inc., 11/2014.
- 3. Package Insert, Liquichek Cardiac Markers PlusControl, Bio-Rad Laboratories, 11/2011.
- 4. Package Insert, CTNI Sample Diluent, Siemens Healthcare Diagnostics Inc., 04/2012.

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
000	3/8/2013	4.2	Added CTNI Diluent onboard stability	A Chini	R SanLuis
000	3/8/2013	10.5	Removed manual dilution, added on board manual dilution	A Chini	R SanLuis
001	2/4/15	5.2	Change in frozen storage temperature	L Barrett	R SanLuis
001	2/4/15	7.2	Change freezer requirements	L Barrett	R SanLuis
001	2/4/15	Footer	Version # leading zero's dropped due to new EDCS in use as of 10/7/13	L Barrett	R SanLuis
2	7/6/15	3.2	Specify anticoagulant	L Barrett	R SanLuis
2	7/6/15	4.2	Add hazard warning	L Barrett	R SanLuis
2	7/6/15	6.4, 6.6	Replace LIS with Unity Real Time	L Barrett	R SanLuis
2	7/6/15	11.1	Change upper value from 0.10 to 0.05	L Barrett	R SanLuis
2	7/6/15	11.2	Change critical from ≥0.60 to >0.09	L Barrett	R SanLuis

19. ADDENDA

None

TILL LONG TO THE TOTAL TO

C112, WAH.C108 CONFIDENTIAL: Authorized for internal use only